Description
The compound shows efficacy against both amyloid and tau pathologies through BACE1 modulation, but the molecular mechanism linking BACE1 activity to tau aggregation remains unexplained. Understanding this cross-pathology mechanism is critical for dual-target AD therapeutics.
Gap type: unexplained_observation Source paper: A Polyaminobiaryl-Based β-secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APP (2023, International journal of molecular sciences, PMID:36982363)
Resolution criteria
Resolved when PEL24-199 BACE1 modulation is connected to both amyloid and tau outcomes through measured pathway intermediates. Required evidence: enzyme kinetics confirming non-competitive BACE1 modulation, APP processing product profiles, tau phosphorylation/aggregation assays, neuroinflammation and astrogliosis markers, and target-engagement rescue or counter-perturbation in APP/tau models. Closure requires demonstrating whether tau benefit is downstream of amyloid lowering, altered BACE1 substrates, or an off-target mechanism.